Retraction: Influences of chronic mild stress exposure on motor, non-motor impairments and neurochemical variables in specific brain areas of MPTP/Probenecid induced neurotoxicity in mice (PLoS ONE (2016) 11:1 (e0146671) DOI: 10.1371/journal.pone.0146671);Influences of chronic mild stress exposure on motor, non-motor impairments and neurochemical variables in specific brain areas of MPTP/probenecid induced neurotoxicity in mice

PLoS ONE

Volumn 11, Issue 1, 2016, Pages

  Janakiraman, Udaiyappan ^a   Manivasagam, Thamilarasan ^a   Thenmozhi, Arokiasamy Justin ^a   Essa, Musthafa Mohamed ^b   Barathidasan, Rajamani ^c   SaravanaBabu, Chidambaram ^c   Guillemin, Gilles J ^d   Khan, Mohammed A S ^e  

^a ANNAMALAI UNIVERSITY   (India)

^b SULTAN QABOOS UNIVERSITY   (Oman)

^c SRI RAMACHANDRA UNIVERSITY   (India)

^d MACQUARIE UNIVERSITY   (Australia)

^e SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; DOPAMINE; DOPAMINE TRANSPORTER; NEUROTOXIN; PROBENECID; SEROTONIN; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2; SLC18A2 PROTEIN, MOUSE; VESICULAR MONOAMINE TRANSPORTER;

ANHEDONIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR ASSESSMENT; BEHAVIOR DISORDER; BRAIN FUNCTION; BRAIN LEVEL; BRAIN REGION; CHRONIC MILD STRESS; CHRONIC STRESS; CONTROLLED STUDY; DEPRESSION; DISEASE ACTIVITY; DISEASE ASSOCIATION; FUNCTIONAL ASSESSMENT; MALE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOTOR DYSFUNCTION; MOUSE; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; ANIMAL; ANTIBODY SPECIFICITY; BRAIN; C57BL MOUSE; COMPLICATION; INTOXICATION; LOCOMOTION; MENTAL STRESS; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DOPAMINE; LOCOMOTION; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; ORGAN SPECIFICITY; PROBENECID; SEROTONIN; STRESS, PSYCHOLOGICAL; TYROSINE 3-MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84955317992     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0236885     Document Type: Erratum

References (72)

1. Hornykiewicz O (1975) Brain monoamines and parkinsonism. Natl Inst Drug Abuse Res Monogr Ser 3: 13-21. PMID: 787796
2. Uc EY, Tippin J, Chou KL, Erickson BA, Doerschug KC, Jimmeh Fletcher DM (2012) Non-motor Symptoms in Parkinson's Disease. European Neurological Review 7: 35-40. doi: 10.17925/ENR.2012.07.01.35
3. Modugno N, Lena F, Dibiasio F, Cerrone G, Ruggieri S, Fornai F (2013) A clinical overview of nonmotor symptoms in Parkinson's disease. Archives Italiennes de Biologie 151: 148-168. PMID: 24873924
4. Swaab DF, Bao AM, Lucassen PJ (2005) The stress system in the human brain in depression and neurodegeneration. Ageing Res Rev 4: 141-194. PMID: 15996533
5. Aarsland D, Marsh L, Schrag A (2009) Neuropsychiatric symptoms in Parkinson's disease. Mov Disord 24: 2175-2186. doi: 10.1002/mds.22589 PMID: 19768724
6. Goetz CG, Tanner CM, Penn RD, Stebbins GT, Gilley DW, Shannon KM et al. (1990) Adrenal medullary transplant to the striatum of patients with advanced Parkinson's disease: 1-year motor and psychomotor data. Neurology 40: 273-276. PMID: 2300248
7. Treves TA, Rabey JM, Korczyn AD (1990) Case-control study, with use of temporal approach, for evaluation of risk factors for Parkinson's disease. Movement Dis 5: 11.
8. Smith AD, Castro SL, Zigmond MJ (2002) Stress-induced Parkinson's disease: a working hypothesis. Physiol Behav 77: 527-531. PMID: 12526994
9. Smith LK, Jadavji NM, Colwell KL, Katrina Perehudoff S, Metz GA (2008) Stress accelerates neural degeneration and exaggerates motor symptoms in a rat model of Parkinson's disease. Eur J Neurosci 27: 2133-2146. doi: 10.1111/j.1460-9568.2008.06177.x PMID: 18412632
10. Hemmerle AM, Dickerson JW, Herman JP, Seroogy KB (2014) Stress exacerbates experimental Parkinson's disease. Mol Psychiatry 19: 638-640. doi: 10.1038/mp.2013.108 PMID: 23999522
11. Monroe SM, Torres LD, Guillaumot J, Harkness KL, Roberts JE, Frank E et al. (2006) Life stress and the long-term treatment course of recurrent depression: Non severe life events predict recurrence for medicated patients over 3 years. J Consult Clin Psychol 74: 112-120. PMID: 16551148
12. Willner P (2005) Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 52: 90-110. PMID: 16037678
13. Schrag A (2006) Quality of life and depression in Parkinson's disease. J Neurol Sci 248: 151-157. PMID: 16797028
14. McEwen BS (2005) Glucocorticoids, depression, and mood disorders: structural remodeling in the brain. Metabolism 54: 20-23. PMID: 15877308
15. Pacak K, Palkovits M (2001) Stressor specificity of central neuroendocrine responses: implications for stress-related disorders. Endocr Rev 22: 502-548. PMID: 11493581
16. Alalade E, Denny K, Potter G, Steffens D, Wang L (2011) Altered cerebellar-cerebral functional connectivity in geriatric depression. PLoS ONE. 6: e20035. doi: 10.1371/journal.pone.0020035 PMID: 21637831
17. Petroske E, Meredith GE, Callen S, Totterdell S, Lau YS (2001) Mouse model of parkinsonism: a comparison between Subacute MPTP and chronic MPTP/probenecid treatment. Neurosci 106: pp. 589-601.
18. Willner P, Towell A, Sampson D, Sophokclous S, Muscat R (1987) Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 93: 358-64. PMID: 3124165
19. RajaSankar S, Manivasagam T, Surendran S (2009) Ashwagandha leaf extract: a potential agent in treatingoxidative damage and physiological abnormalities seen in amouse model of Parkinson's disease. Neurosci Lett 454: 11-15. doi: 10.1016/j.neulet.2009.02.044 PMID: 19429045
20. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275. PMID: 14907713
21. Franklin KBJ, Paxinos G (2007) The mouse brain in stereotaxic coordinates. London: Academic Press.
22. Abercrombie M (1946) Estimation of nuclear population from microtome sections. Anat Rec 94:239-247. PMID: 21015608
23. Nicklas WJ, Youngster SK, Kindt MV (1987) MPTP, MPP+ and mitochondrial function. Life Sci 40: 721-729. PMID: 3100899
24. Anandhan A, Tamilselvam K, Radhiga T, Rao S, Essa MM, Manivasagam T (2012) Theaflavin, a black tea polyphenol, protects nigral dopaminergic neurons against chronic MPTP/probenecid induced Parkinson's disease. Brain Res 1433: 104-113. doi: 10.1016/j.brainres.2011.11.021 PMID: 22138428
25. Lohle M, Storch A, Reichmann H (2009) Beyond tremor and rigidity: non-motor features of Parkinson's disease. J Neural Transm 116: 1483-1492. doi: 10.1007/s00702-009-0274-1 PMID: 19680598
26. Mayeux R (1990) Depression in the patient with Parkinson's disease. J Clin Psychiatry 51: 24-5. PMID: 2195009
27. Mayeux R, Williams JB, Stern Y, Cote L (1984) Depression and Parkinson's disease. Adv Neurol 40: 241-50.
28. Pain S, Gochard A, Bodard S, Gulhan Z, Prunier-Aesch C, Chalon S (2013) Toxicity of MPTP on neurotransmission in three mouse models of Parkinson's disease. Exp Toxicol Pathol 65: 689-94. doi: 10. 1016/j.etp.2012.09.001 PMID: 23083629
29. Vancassel S, Leman S, Hanonick L, Denis S, Roger J, Nollet M et al. (2008) n-3 polyunsaturated fatty acid supplementation reverses stressinduced modifications on brain monoamine levels in mice. J Lipid Res 49: 340-348. PMID: 17991757
30. Luchtman DW, Shao D, Song C (2009) Behavior, neurotransmitters and inflammation in three regimens of the MPTP mouse model of Parkinson's disease. Physiol Behav 98: 130-138. doi: 10.1016/j. physbeh.2009.04.021 PMID: 19410592
31. Luchtman DW, Meng Q, Song C (2012) Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease. Behav Brain Res 226: 386-396. doi: 10.1016/j.bbr.2011.09.033 PMID: 21971013
32. Javelot H, Messaoudi M, Jacquelin C, Bisson JF, Rozan P, Nejdi A et al. (2014) Behavioral and neurochemical effects of dietary methyl donor deficiency combined with unpredictable chronic mild stress in rats. Behav Brain Res 261: 8-16. doi: 10.1016/j.bbr.2013.11.047 PMID: 24333542
33. Abercrombie ED, Keefe KA, DiFrischia DF, Zigmond MJ (1989) Differential effects of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal cortex. J Neurochem 52: 1655-1658. PMID: 2709017
34. Keefe KA, Stricker EM, Zigmond MJ, Abercrombie ED (1990) Environmental stress increases extracellular dopamine in striatum of 6-hydroxydopamine-treated rats: in vivo micro dialysis studies. Brain Res 527: 350-353. PMID: 2123730
35. Alex KD, Pehek EA (2007) Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol Ther 113: 296-320. PMID: 17049611
36. Michelsen KA, Prickaerts J, Steinbusch HW (2008) The dorsal raphe nucleus and serotonin: implications for neuroplasticity linked to major depression and Alzheimer's disease. Prog Brain Res 172: 233-246. doi: 10.1016/S0079-6123(08)00912-6 PMID: 18772036
37. Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M et al. (2008) Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 131: 120-131. PMID: 17956909
38. Hirsch EC, Orieux G, Muriel MP, Francois C, Feger J (2003) Nondopaminergic neurons in Parkinson's disease. Adv Neurol 91: 29-37. PMID: 12449099
39. Vriend C, Pattij T, van der Werf YD, Voorn P, Booij J, Rutten S et al. (2013) Depression and impulse control disorders in Parkinson's disease: two sides of the same coin? Neurosci Biobehav Rev 38C: 60-71. doi: 10.1016/j.neubiorev.2013.11.001 PMID: 24239733
40. Jay TM, Rocher C, Hotte M, Naudon L, Gurden H, Spedding M (2004) Plasticity at hippocampal to prefrontal cortex synapses is impaired by loss of dopamine and stress: Importance for Psychiatric diseases. Neurotox Res 6: pp. 233-244. PMID: 15325962
41. De Deurwaerdere P, Navailles S, Berg KA, Clarke WP, Spampinato U (2004) Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J Neurosci 24: 3235-3241. PMID: 15056702
42. Di Matteo V, Cacchio M, Di Giulio C, Esposito E (2002) Role of serotonin (2C) receptors in the control of brain dopaminergic function. Pharmacol Biochem Behav 71: 727-734. PMID: 11888564
43. Jacobs BL, Fornal CA (1993) 5-HT and motor control: a hypothesis. Trends Neurosci 16: 346-352. PMID: 7694403
44. Van Praag HM, De Haan S (1979) Central serotonin metabolism and frequency of depression. Psychiatry Res 1: 219-224. PMID: 95233
45. Benloucif S, Galloway MP (1991) Facilitation of dopamine release in vivo by serotonin agonists: studies with microdialysis. Eur J Pharmacol 200: 1-8. PMID: 1769366
46. Benloucif S, Keegan MJ, Galloway MP (1993) Serotonin-facilitated dopamine release in vivo: pharmacological characterization. J Pharmacol Exp Ther 265: 373-377. PMID: 8474019
47. Dremencov E, Newman ME, Kinor N, Blatman-Jan G, Schindler CJ, Overstreet DH et al. (2005) Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment. Neuropharmacology 48: 34-42. PMID: 15617725
48. Heikkila RE, Sonsalla P (1992) The MPTP-treated mouse as a model of parkinsonism: How good is it. Neurochem Int 20: 299-303. PMID: 1365446
49. Miller GW, Erickson JD, Perez JT, Penl SN, Mash DC, Rye DB et al. (1999) Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp Neurol 156: 138-148. PMID: 10192785
50. Ahmad SO, Park JH, Bittel LS, Lau YS (2009) Effects of endurance exercise on ventral tegmental area neurons in the chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and probenecid-treated mice. Neurosci Lett 450: 102-105. doi: 10.1016/j.neulet.2008.11.065 PMID: 19084578
51. Dawson TM (2000) New animal models for Parkinson's disease. Cell 101: 115-118. PMID: 10786830
52. Liu B, Xie JX, Rowlands DK, Gou YL, Leung CC, Chung YW et al. (2004) Neuroprotective effects of Bak Foong Pill in 1-methyl-4-phenyl-1,2,3,6-tetrahyrdropyridine (MPTP)-induced Parkinson's disease model mice. Biol Pharm Bull 27: 1245-50. PMID: 15305030
53. Lisman JE, Grace AA (2005) The hippocampal-VTA loop: controlling the entry of information into longterm memory. Neuron 46: 703-13. PMID: 15924857
54. Rasheed N, Ahmad A, Al-Sheeha M, Alghasham A, Palit G (2011) Neuroprotective and anti-stress effect of A68930 in acute and chronic unpredictable stress model in rats. Neurosci Lett 504: 151-15. doi: 10.1016/j.neulet.2011.09.021 PMID: 21945949
55. 3H)mazindol binding sites in rat straitum by dopaminergic agents. Eur J Pharmacol 250: 261-266. PMID: 7906653
56. Schmitz Y, Lee CJ, Schamauss C, Gonon F, Sulzer D (2001) Amphetamine distorts stimulation-dependent dopamine overflow: effects on D2 auto receptors, transporters, and synaptic vesicle stores. J Neurosci 21: 5916-5924. PMID: 11487614
57. Brown AS, Gershon S (1993) Dopamine and depression. J Neural Transm Gen Sect 91: 75-109. PMID: 8099801
58. Hashimoto M, Hsu LJ, Sisk A, Xia Y, Takeda A, Sundsmo M et al. (1998) Human recombinant NACP/ alpha-synuclein is aggregated and fibrillated in vitro: relevance for Lewy body disease. Brain Res 799: 301-306. PMID: 9675319
59. Itoi K, Sugimoto N (2010) The brainstem noradrenergic systems in stress, anxiety and depression. J Neuroendocrinol 22: 355-361. doi: 10.1111/j.1365-2826.2010.01988.x PMID: 20210846
60. Lowry CA, Hale MW, Evans AK, Heerkens J, Staub DR, Gasser PJ et al. (2008) Serotonergic systems, anxiety, and affective disorder: focus on the dorsomedial part of the dorsal raphe nucleus. Ann N Y Acad Sci 1148: 86-94. doi: 10.1196/annals.1410.004 PMID: 19120094
61. Braak H, Bohl JR, Müller CM, Rüb U, de Vos RA, Del Tredici K (2006) Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 21: 2042-2051. PMID: 17078043
62. Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE et al. (2000) Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 15: 669-677. PMID: 10928577
63. Crabbe JC, Metten P, Chia-Hua Y, Schlumbohm JP, Cameron AJ, Wahlsten D (2003) Genotypic differences in ethanol sensitivity in two tests of motor in coordination. J Appl Physiol 95: 1338-1351. PMID: 12704090
64. Bhattacharya SK, Bhattacharya A, Chakrabarti A (2000) Adaptogenic activity of Siotone, a polyherbal Ayurvedic rasayana formulation. Indian J Exp Biol 38: 119-128. PMID: 11218827
65. Anisman H, Zacharko RM (1982) Depression: the predisposing influence of stress. Behav Brain Sci 5: 89-137. doi: 10.1017/S0140525X00010633
66. Fleming SM, Salcedo J, Fernagut P-O, Rockenstein E, Masliah E, Levine MS et al. (2004) Early and progressive sensorimotor anomalies in mice overexpressing wild-type human α-synuclein. J Neurosci 24: 9434-9440. PMID: 15496679
67. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 51: 8-19. PMID: 8279933
68. Wise RA (1985) The anhedonia hypothesis: mark III. Behav Brain Sci 8: 178-186.
69. Harrison AA, Markou A (2001) Serotonergic manipulations both potentiate and reduce brain stimulation reward in rats: involvement of serotonin-1A receptors. J Pharmacol Exp Ther 297: 316-325. PMID: 11259559
70. Deutch AY, Bourdelais AJ, Zahm DS (1993) The nucleus accumbens core and shell: accumbal compartments and their functional attributes. In: Kalivas P.W., Barnes C.D., (Eds.), Limbic Motor Circuits and Neuropsychiatry. CRC Press, Boca Raton, FL, pp. 45-88.
71. Deutch AY, Tam SY, Roth RH (1985) Footshock and conditioned stress increase 3,4-dihydroxyphenylacetic acid (DOPAC) in the ventral tegmental area but not substantia nigra. Brain Res. 333, 143-146. PMID: 3995282
72. McDonald WM, Richard IH, DeLong MR (2003) Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 54: 363-375. PMID: 12893111